BACKGROUND: Most cancers occur more frequently in men. Numerous explanations for this excess risk have been proposed, yet no study has quantified the degree to which height explains the sex difference even though greater height has been associated with increased risk for many cancers. METHODS: During the period from 2000 to 2002, 65308 volunteers aged 50 to 76 years were recruited to the Vitamins And Lifestyle (VITAL) study. Cancers of shared anatomic sites (n = 3466) were prospectively identified through 2009 through the Surveillance, Epidemiology, and End Results cancer registry. Age- and race-adjusted hazard ratios (HRs) for the associations between sex and incident cancers were estimated using Cox proportional hazards models, with and without adjustment for height and height squared as measures of body size. RESULTS: Men had a 55% increased risk of cancer at shared sites (HR = 1.55; 95% confidence interval [CI] = 1.45 to 1.66). When height was accounted for, 33.8% (95% CI = 10.2% to 57.3%) of the excess risk for men was explained by the height differences between sexes. The proportion mediated by height was 90.9%, 57.3%, and 49.6% for kidney, melanoma, and hematologic malignancies, respectively, with little evidence that height mediates the sex difference for gastrointestinal tract, lung, and bladder cancers. For comparison, more than 35 lifestyle and medical risk factors only explained 23.1% of the sex difference in cancer risk at shared sites. CONCLUSIONS: Height is an important explanatory factor for the excess risk for men for many shared-site cancers. This suggests that some of the excess risk is due to factors associated with height (eg, number of susceptible cells in a specific organ or growth-influencing exposures in childhood).
BACKGROUND: Most cancers occur more frequently in men. Numerous explanations for this excess risk have been proposed, yet no study has quantified the degree to which height explains the sex difference even though greater height has been associated with increased risk for many cancers. METHODS: During the period from 2000 to 2002, 65308 volunteers aged 50 to 76 years were recruited to the Vitamins And Lifestyle (VITAL) study. Cancers of shared anatomic sites (n = 3466) were prospectively identified through 2009 through the Surveillance, Epidemiology, and End Results cancer registry. Age- and race-adjusted hazard ratios (HRs) for the associations between sex and incident cancers were estimated using Cox proportional hazards models, with and without adjustment for height and height squared as measures of body size. RESULTS:Men had a 55% increased risk of cancer at shared sites (HR = 1.55; 95% confidence interval [CI] = 1.45 to 1.66). When height was accounted for, 33.8% (95% CI = 10.2% to 57.3%) of the excess risk for men was explained by the height differences between sexes. The proportion mediated by height was 90.9%, 57.3%, and 49.6% for kidney, melanoma, and hematologic malignancies, respectively, with little evidence that height mediates the sex difference for gastrointestinal tract, lung, and bladder cancers. For comparison, more than 35 lifestyle and medical risk factors only explained 23.1% of the sex difference in cancer risk at shared sites. CONCLUSIONS: Height is an important explanatory factor for the excess risk for men for many shared-site cancers. This suggests that some of the excess risk is due to factors associated with height (eg, number of susceptible cells in a specific organ or growth-influencing exposures in childhood).
Authors: Luisa Zuccolo; Ross Harris; David Gunnell; Steven Oliver; Jane Athene Lane; Michael Davis; Jenny Donovan; David Neal; Freddie Hamdy; Rebecca Beynon; Jelena Savovic; Richard Michael Martin Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-09 Impact factor: 4.254
Authors: D Gunnell; S E Oliver; J L Donovan; T J Peters; D Gillatt; R Persad; F C Hamdy; D E Neal; J M P Holly Journal: J Clin Endocrinol Metab Date: 2004-01 Impact factor: 5.958
Authors: Emily White; Ruth E Patterson; Alan R Kristal; Mark Thornquist; Irena King; Ann L Shattuck; Ilonka Evans; Jessie Satia-Abouta; Alyson J Littman; John D Potter Journal: Am J Epidemiol Date: 2004-01-01 Impact factor: 4.897
Authors: L Mellemkjær; J Christensen; K Frederiksen; J L Baker; A Olsen; T I A Sørensen; A Tjønneland Journal: Br J Cancer Date: 2012-06-07 Impact factor: 7.640
Authors: Alain Monnereau; Susan L Slager; Ann Maree Hughes; Alex Smith; Bengt Glimelius; Thomas M Habermann; Sonja I Berndt; Anthony Staines; Aaron D Norman; James R Cerhan; Joshua N Sampson; Lindsay M Morton; Jacqueline Clavel Journal: J Natl Cancer Inst Monogr Date: 2014-08
Authors: Sam M Mbulaiteye; Lindsay M Morton; Joshua N Sampson; Ellen T Chang; Laura Costas; Silvia de Sanjosé; Tracy Lightfoot; Jennifer Kelly; Jonathan W Friedberg; Wendy Cozen; Rafael Marcos-Gragera; Susan L Slager; Brenda M Birmann; Dennis D Weisenburger Journal: J Natl Cancer Inst Monogr Date: 2014-08
Authors: Aaron P Thrift; Harvey A Risch; Lynn Onstad; Nicholas J Shaheen; Alan G Casson; Leslie Bernstein; Douglas A Corley; David M Levine; Wong-Ho Chow; Brian J Reid; Yvonne Romero; Laura J Hardie; Geoffrey Liu; Anna H Wu; Nigel C Bird; Marilie D Gammon; Weimin Ye; David C Whiteman; Thomas L Vaughan Journal: Clin Gastroenterol Hepatol Date: 2014-02-12 Impact factor: 11.382